Interleukin 22 Receptor (IL22R) - Drugs in Development, 2021
Summary Interleukin 22 Receptor (IL22R) - Drugs in Development, 2021 provides in depth analysis on Interleukin 22 Receptor (IL22R) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in Interleukin 22 Receptor (IL22R) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products across relevant therapy areas under development targeting Interleukin 22 Receptor (IL22R).
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: * This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase. * Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the Global therapeutic landscape for Interleukin 22 Receptor (IL22R). - The report reviews Interleukin 22 Receptor (IL22R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. - The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities. - The report reviews key players involved in Interleukin 22 Receptor (IL22R) targeted therapeutics and enlists all their major and minor projects. - The report assesses Interleukin 22 Receptor (IL22R) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. - The report summarizes all the dormant and discontinued pipeline projects. - The report reviews latest news and deals related to Interleukin 22 Receptor (IL22R) targeted therapeutics.
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Identify and understand the targeted therapy areas and indications for Interleukin 22 Receptor (IL22R). Identify the use of drugs for target identification and drug repurposing. - Identify potential new clients or partners in the target demographic. - Develop strategic initiatives by understanding the focus areas of leading companies. - Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics. - Devise corrective measures for pipeline projects by understanding Interleukin 22 Receptor (IL22R) development landscape. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Our reports have been used by over 10K customers, including:
Readers of one of the analyst’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021.The analyst has conducted similar studies among the same targeted respondents since 2012.
Where applicable, the study presents year-over-year...
175 pages •
By The Business Research Company
• Jun 2021
Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, and Roche Holdings AG The global enzymes market is expected to grow from $7.81 billion in 2020 to $8.9 billion in 2021 at a compound annual growth rate (CAGR)...
Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1) - Drugs in Development, 2021 Summary Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
529 pages •
By Global Industry Analysts
• Apr 2021
- Global Drug Discovery Technologies Market to Reach $74.3 Billion by 2027
- Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$44.2 Billion in the year 2020, is projected to reach a revised size of US$74.3 Billion by 2027, growing at aCAGR of 7.7% over the period...
Global Hospital Care Partnering 2014 to 2021 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital...
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
The Global Microbiome Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Microbiome partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Microbiome partnering deals Disclosed headlines, upfronts, milestones and royalties by...
The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.